



neurosciencesvictoria

2009 | 2010
ANNUAL REPORT





TABLE OF CONTENTS

CHAIRMAN AND CEO REPORT	1
OVERVIEW.....	2
• CAPABILITIES AND DISEASE SPECIALISATIONS	2
BOARD OF DIRECTORS	3
MEMBERS	6
• BRAIN RESEARCH INSTITUTE	6
• HOWARD FLOREY INSTITUTE	6
• NATIONAL STROKE RESEARCH INSTITUTE	6
• CENTRE FOR EYE RESEARCH AUSTRALIA	8
• MENTAL HEALTH RESEARCH INSTITUTE	9
• MONASH UNIVERSITY.....	10
• SWINBURNE UNIVERSITY OF TECHNOLOGY	11
• UNIVERSITY OF MELBOURNE	12
BOARD ADVISORY COMMITTEES	13
• RISK AND AUDIT COMMITTEE	13
• SCIENTIFIC ADVISORY COUNCIL	14
NSV TEAM.....	15
FINANCIALS.....	16

CHAIRMAN AND CEO REPORT

Neurosciences Victoria has completed its tenth year of operations, and on behalf of the Board of the Company we are pleased to report on another year of solid achievement.

NSV continues to perform strongly and be self sustaining, with revenues in 2009/10 of \$1.16 million, profit of \$24,000 and equity of \$2.18 million. This has been the fifth consecutive year that the Company has operated profitably, and we believe its business model is highly appropriate for our present activities and strategic direction.

NSV plays a unique role in Victoria, a major centre for neuroscience in Australia. Over the course of NSV's history, the Company - in close partnership with its Members - has generated over \$63 million in external revenues for neuroscience research. Working with key neuroscience research organisations to facilitate major world-leading programs, our focus is to make a significant impact on diseases of the brain and mind.

Our strong relationships with the research, government and industry sectors and our ability to foster collaborative programs are important factors in helping to secure research funding. NSV's role, assisting in the management of programs, optimises successful implementation. The Company, through its Members, is currently involved in programs related to stroke, Alzheimer's disease, schizophrenia, Parkinson's disease, pain, depression, epilepsy, multiple sclerosis and trauma. NSV and its Members are working towards earlier and more accurate diagnosis and treatment of such diseases, identifying at-risk populations for targeted treatment programs and seeking new therapy opportunities. NSV will continue to assist its world-class researchers in the universities, medical research institutes and hospitals to search for new answers to address these major burdens of disease.

We expect 2010/11 will prove to be another strong year for NSV and Victorian neuroscience as we continue to expand our activities and develop new opportunities in areas of major unmet medical need. We would like to thank all of our fellow Directors, NSV's staff and the members of our Scientific Advisory Council for their continued support and involvement.



A handwritten signature in black ink, appearing to read 'Bill Burdett'.

Bill Burdett
CHAIRMAN



A handwritten signature in black ink, appearing to read 'Andrew Milner'.

Andrew Milner PhD
CHIEF EXECUTIVE OFFICER

OVERVIEW

Neurosciences Victoria is the marketing organisation for an Australian world-class neuroscience cluster. We offer a single access point to a series of neuroscience technology-based platforms and disease specialisations, backed by leading neurology and psychiatry resources and clinical expertise. One of our main aims is to facilitate seamless contractual relationships between industry, government and the neuroscience cluster of universities, medical research institutes and major hospitals. To date, NSV has generated in excess of \$63m in revenues for the neuroscience cluster.

The principal products and services of NSV relate to the pre-clinical and clinical neuroscience expertise in pharmaceuticals, diagnostics and medical devices relevant to the global marketplace which reside within its Member organisations. The major product opportunities relate to contract services in which revenue is generated from external customers who access the skills and infrastructure within the Member organisations.

NSV typically acts as a conduit for external customers for large scale, multi-institute programs. This ability to act as a 'one-stop shop' is one of the key competitive advantages of NSV, both within Australia and internationally.

NSV also provides advice and leadership to other business activities such as providing high-level management and assistance in financing activities to spin out companies.

NSV operates as a self sustaining business, growing revenues and controlling costs to ensure its viability for the foreseeable future.

CAPABILITIES AND DISEASE SPECIALISATIONS

NSV markets the following Technology Platforms.

- **Neuroscience Trials Australia**
Facilities include Clinical Trial Design (assessment of feasibility, assistance with human ethics approvals, matching study sponsors with suitable investigators) and Databases (design and management, access to existing databases and data collection).
- **Neuro Research Services (formerly Integrative Neuroscience Facility)**
Facilities include Rodent Surgical Techniques, Advanced Morphology and Microscopy, *in vivo* pre-clinical testing and Behavioural Phenotyping.
- **Cell Physiology, Histology and Imaging**
Facilities include the Confocal Microscope, Electrophysiological Testing, Evaluation of Channels as Targets, Immunohistochemistry and Histology.

- **Neuroscience Informatics**
Neuroscience informatics cover three research areas including development of (i) neuroscience databases and knowledge bases, (ii) electronic tools for neuroscience data analysis, and (iii) computational modelling of the brain.
- **Clinical Neurobiology of Psychiatry**
Facilities include EEG/ERP systems, a GAITrite gait analysis system, an Eyelink video eye tracking system and a Transcranial Direct Current Stimulator.
- **Neuroimaging**
Facilities include PET, Large Bore MRI, Small Animal MRI.
- **Neuroproteomics and Neurogenomics**
Facilities include Genomics Sequencing and Genotyping, Real Time PCR, Protein Arrays and Expression, SELDI, HPLC and Bioinformatics.
- **Australian Brain Bank Network**
Facilities include Application Specific Brain Banks, Research Material, Neuropathologic Diagnostic Service and a Brain Donor program.

NSV works with the following Disease Specialisations.

- Multiple sclerosis
- Schizophrenia
- Alzheimer's disease
- Epilepsy
- Neurodevelopmental disease
- Depression and bipolar disorder
- Huntington's disease
- Motor Neurone Disease/ALS
- Neurotrauma
- Parkinson's disease
- Stroke

BOARD OF DIRECTORS

The Board of Directors of Neurosciences Victoria, chaired by Mr Bill Burdett, brings together a balance of scientific, public policy and commercial expertise.



Mr Bill Burdett
BSc (Hons), ASIA
CHAIRMAN

Mr Burdett graduated in geology at the University of Western Australia and worked in oil exploration for nine years before moving to Melbourne to start a mining research department for the stockbroking firm of A.C. Goode & Co.

In 1988 Bill was the Founding Chairman and Chief Executive of Burdett, Buckeridge & Young, an institutional stockbroker. He is currently a director of Investment Technology Group, Inc. (ITG), listed on the New York Stock Exchange and IRESS Market Technology Ltd., listed on the ASX.

He is a Council Member of the Nossal Institute for Global Health and a Director of the Victorian Neurotrauma Initiative Pty. Ltd. and of the Australian International Health Institute, a not-for-profit company of The University of Melbourne, which aims to build capacity in public health services in the Asia-Pacific.



Mrs Jan West AM
B.Comm, FCA
DEPUTY CHAIR

Mrs West commenced her career in 1975, joining Deloitte Touche Tohmatsu Melbourne after receiving her Bachelor of Commerce from the University of Melbourne. She is the National Leader, Professional Standards Review having specialised in Assurance and

Advisory, with a focus on manufacturing, consumer business and services industries.

A Partner since 1988, Jan has provided professional services to a wide range of public companies and large businesses operating within Australia and internationally and has worked extensively with audit committees on control, governance and operational best practice benchmarking.

Jan was appointed a Member of the Financial Reporting Council in 2005. She held the position of National President and Chairman of the Board of The Institute of Chartered Accountants in Australia (ICAA) during 2001. Jan was Honorary Treasurer of the National Trust of Australia (Victoria) for eight years, a Board member of EcoRecycle Victoria for four years and is currently the Chair of the Professional Conduct Tribunal of the ICAA. She was awarded the Order of Australia in 2007 and the Governor General's Centenary Medal in 2003.

Jan is a Fellow of the ICAA and of CPA Australia and a member of the Australian Institute of Company Directors.



Professor Ed Byrne AO
DSc, MD, MBA, FRACP, FRCPE, FRCP (Lond)

Professor Byrne is the Vice Chancellor and President of Monash University. He has had an active career in clinical neurology and basic neurological research. He received his MBBS with first class honours from the University of Tasmania in 1974 and moved to Adelaide the following year, becoming Neurology Registrar in 1977. During the years 1980-82, he was the Muscular Dystrophy Research Fellow at Queen Square in London. In 1983, he returned to Australia to be Director of Neurology at St Vincent's Hospital Melbourne, becoming Professor/Director in 1992.

Ed was awarded the degree of Doctor of Science from The University of Melbourne in 1995. He was the Founding Director of the Melbourne Neuromuscular Research Institute and the Founding Director of the Centre for Neuroscience and Professor of Experimental Neurology at the University of Melbourne. As Director of the Centre for Neuroscience, he played a major role in driving the establishment of Neurosciences Victoria and Neurosciences Australia. He is a Director of BUPA Pty and Cochlear Pty Ltd and immediate past Editor-in-Chief of the Internal Medicine Journal.

He is a member of the Neuromuscular Steering Group of the World Federation of Neurology. He was Secretary General and Chair of the program committee of the 9th International Neuromuscular Congress. He has served as a Governor of BHP Billiton Charitable Trustees and a Board Member of the Baker Heart Research Institute, Prince Henry's Institute of Medical Science, McFarlane Burnet Centre for Medical Research, Monash Institute of Medical Research and Southern Health.

He was awarded the Queen's Square prize for Neurological Research in 1982, the Bethlehem Griffiths Research Medal in 2003 and the Sir Louis Pyke Award for contribution to Multiple Sclerosis in 2004. He was awarded an Officer of the Order of Australia in the 2006 Australia Day Honours List and was selected as University of Tasmania's Alumnus of the Year in 2010. Professor Byrne was Dean of Medicine, Nursing and Health Sciences at Monash University (2003-07) and Executive Dean of Biomedicine, University College London and Head of the Royal Free University College Medical School and Vice Provost at University College London (2007-09).



Professor Geoffrey Donnan
MD, FRACP, FRCP

Professor Donnan is the Director of the Florey Neuroscience Institutes. He was Professor of Neurology, University of Melbourne, 1993-2008 and is the past Director of the National Stroke Research Institute. Geoff's research interest is clinical stroke management and he was co-founder of the Australian

Stroke Trials Network and Neuroscience Trials Australia. He is past President of the World Stroke Organisation and received the American Stroke Association William Feinberg award for excellence in clinical stroke research in 2007.



Professor John Furness
MSc, PhD, FAA

Professor Furness is the co-Director of the Autonomic Neuroscience, Pain and Sensory Mechanisms Laboratories, Department of Anatomy and Cell Biology at the University of Melbourne. He is Platform Leader of the Cell Physiology, Histology and Imaging Platform, and Node Leader of the Australian Phenomics Network

(Melbourne).

He is best known for the chemical coding hypothesis that has strongly influenced studies of the organisation of nerve circuits, for his work in unravelling the intrinsic circuits in the digestive tract and for the discovery and characterisation of sensory neurons intrinsic to the digestive tract.

The major focuses of John's current work are on autonomic consequences of spinal cord injury, autonomic neuropathies, visceral sensory neurons, the investigation of drugs that reduce visceral pain and on the control of ion channels that determine the excitabilities of neurons.

Professor Furness was elected a Fellow of the Australian Academy of Science in 1989. He received the Janssen International Research Award in 1993, the Davenport Medal of the American Physiological Society in 1997, the Distinguished Achievement Award of the Australian Neuroscience Society in 2003 and a Centenary Medal in 2003. He was elected Fellow of the Academy of Science of Bologna (L'accademia delle scienze dell'istituto di Bologna), the world's second oldest scientific academy, in 2005.



Professor Graeme Jackson
BSc (Hons), MD, FRACP

Professor Graeme Jackson is the Director of the Brain Research Institute, a subsidiary of the Florey Neuroscience Institutes, of which he is also a Director. His primary research interest is the application of Magnetic Resonance Imaging (MRI) techniques to the understanding of epilepsy and brain function.

Graeme holds a number of other positions, both clinical and academic. He is a Professorial Fellow of the Department of Medicine, Austin Health, The University of Melbourne. In recognition of his ability to integrate imaging modalities with biological questions, he also holds an academic appointment in the Department of Radiology at The University of Melbourne. Graeme is a neurologist at the Austin Hospital. He was awarded the National Health and Medical Research Council Excellence Award in 2008.

His major research achievement is his impact on the understanding of epilepsy. He is a world leader on the use of imaging technologies in neurological disease and has combined these interests to advance the understanding of epilepsy and to identify lesions that allow surgical cure of epilepsy.



Mr Bruce Kean AM
Dip ChemE, FIEAus, FTS, FAICD, FRSA

Mr Kean was educated in Melbourne, studying Chemical Engineering and Economics. He retired as a Director of Folkestone Ltd. in 2008 and has served on the boards of many public companies, including as Managing Director of Boral Ltd (1987-94) and a Director of AMP (1989-2000).

In community affairs, Bruce is currently Chair of the ATSE Clunies Ross Foundation. He is also the Chairman of the APEC Study Centre Advisory Board of the Royal Melbourne Institute of Technology and is a Governor of both the Mental Health Research Institute and the Florey Neuroscience Institutes.

He was Chair of the Committee for Economic Development of Australia (1994-2002), Chair of The Sir David Martin Foundation (1994-98) and Chair of The Mental Health Research Institute of Victoria (2001-08). He was a member of the Prime Minister's Economic and Planning Advisory Committee (1992-94) and Chair of the Commonwealth Government's Committee of Inquiry into the Standards and Conformance Infrastructure of Australia (1994-95). In 1994 he was awarded the Order of Australia and later the Governor General's Centenary Medal.



Professor Trevor Kilpatrick

MBBS, PhD, FRACP

Professor Kilpatrick is a clinician scientist whose basic research focuses on the neurobiology of multiple sclerosis, in particular oligodendrocytic biology and regenerative medicine.

Trevor has initiated a number of productive clinical research projects and established multi-centre collaborations to study the genetics and epidemiology of MS and is developing translational platforms for therapeutics that target neurodegenerative diseases. He is Director of the Centre for Neuroscience and the Melbourne Neuroscience Institute at The University of Melbourne and co-ordinates the University's Faculty of Medicine, Dentistry and Health Sciences' research domain in the Neurosciences and Behavioural Sciences. He also heads the Multiple Sclerosis Division at the Florey Neuroscience Institutes and is a neurologist and Head of the MS Unit at the Royal Melbourne Hospital.



Dr Andrew Milner

BSc (Hons), MSc, PhD, FASM
CHIEF EXECUTIVE OFFICER

Dr Milner is the CEO of Neurosciences Victoria and Neurosciences Australia. He is also a non-executive director of STC Ltd, a micro and nano technology consortium. Andrew obtained a BSc (Hons) at the University of Melbourne in 1976, a MSc degree at the

University of Melbourne in 1980 and a PhD at the John Curtin School of Medical Research at the Australian National University in 1983.

Andrew is a Fellow of the Australian Society for Microbiology and has worked in animal health and agriculture as Head of Molecular Biology at the Victorian Institute of Animal Science and subsequently as Operations Manager at Daratech Pty Ltd. In the medical arena, he has worked as Pricing Manager for Zeneca and AstraZeneca in Australia, as Director of Development and Commercialisation for Kendle (Australia) and as Managing Director of Mimotopes Pty Ltd.



Professor Eisdon Storey

MBBS, FRACP, DPhil

Professor Storey is Professor of Neuroscience at Monash University (Alfred Hospital campus), Director of the Van Cleef Roet Centre for Nervous Diseases and Head of the Neurology Unit, Alfred Hospital. Professor Storey's interests are in behavioural neurology and in neurogenetics. In conjunction with geneticists from

Genetics Health Services Victoria he conducts Neurogenetics Clinics at Royal Melbourne, St Vincent's and the Alfred Hospitals. He has also been Neurologist to the Memory Clinic at Caulfield Hospital since 1997.

He has served as Chair of Senior Medical Staff at the Alfred Hospital and is currently a Council Member of the Australian and New Zealand Association of Neurologists (ex officio). He is Neurology Co-Editor of the Journal of Clinical Neuroscience, a Member of the National Brain Foundation's Scientific Advisory Committee and a Trustee of the Bethlehem Griffiths Foundation.



Professor Bruce Tonge

MBBS, MD, DPM, MRC Psych, FRANZCP, Cert Child Psych RANZCP

Professor Tonge is the Head, School of Psychology and Psychiatry and the Head, Discipline of Psychological Medicine, Monash University. He is also Clinical Advisor to the Southern Health Mental Health Program.

Professor Tonge established the internationally recognised Monash University Centre for Developmental Psychiatry and Psychology and conducts research in the areas of autism, intellectual disability and treatment of childhood anxiety and depression. He is a Director of Neurosciences Australia and the Chair of Autism Victoria.

He has produced over 300 publications including the handbook of Studies on Child Psychiatry (Elsevier) and is co-author of the Developmental Behaviour Checklist, which assesses psychopathology in people with intellectual disability. He is a recipient of the Minister of Mental Health Victorian Public Healthcare Award for Outstanding Individual Achievement in Mental Healthcare and the RANZCP Meritorious Award for Outstanding Contribution to Victorian Psychiatry.

Directors Retired in September 2009

- Professor Frederick Mendelsohn AO
- Ms Kate Spargo

COMPANY SECRETARY



Ms Marion Thompson

Ms Thompson has an extensive background in providing executive support at the senior level. Prior to joining NSV in 2002, she spent twenty years in the Victorian public sector.

MEMBERS

NSV currently represents the following eight leading neuroscience research organisations, with new memberships anticipated to occur in the 2010/11 financial year.

- Brain Research Institute
- Howard Florey Institute
- National Stroke Research Institute
- Centre for Eye Research Australia
- Mental Health Research Institute
- Monash University
- Swinburne University of Technology
- University of Melbourne

BRAIN RESEARCH INSTITUTE HOWARD FLOREY INSTITUTE NATIONAL STROKE RESEARCH INSTITUTE

Florey Neuroscience Institutes

JOINING FORCES FOR BRAIN RESEARCH

The amalgamation of the Brain Research Institute, the Howard Florey Institute and the National Stroke Research Institute resulted in the formation of the Florey Neuroscience Institutes (FNI) in July 2007.

The Director, Professor Geoffrey Donnan set about restructuring FNI's research into divisions. Where possible, each division is co-managed by a basic and a clinical researcher. The aim of shared responsibility is to generate collaboration and cross-fertilisation between researchers and the two campuses of the amalgamated group.

Professor Donnan and a newly established Faculty organised the research into the following twelve divisions.

- Imaging
- Behavioral neuroscience
- Multiple sclerosis
- Clinical trials
- Stroke
- Statistics and informatics
- Epilepsy
- Neurodegeneration
- Systems neurophysiology
- Regeneration and plasticity
- Neuropeptides

A BOOST FOR THE BUILDING PROCESS

Announced in the 2009 Federal budget, the Commonwealth provided FNI and its partners with an additional \$39.8 million towards the building project. Through an FNI-led application to the Health and Hospitals Fund, this substantial contribution provides financial security to the project. FNI, the University of Melbourne and the Mental Health Research Institute are very grateful for the Commonwealth's ongoing support of the project.

THE BUILDINGS TAKE SHAPE

Building progress has been rapid through 2009/10. Both the Austin and Parkville sites are making a substantial visual impact within their precincts.

The shells of both buildings have been completed and the internal fit-out of the Austin Campus is being undertaken with the view to the relocation occurring either in late 2010 or early 2011.

The Parkville site is on track for completion by mid 2011 and should be occupied by the end of that year.

BRAIN DISORDER RESEARCH FOCUS

Ground-breaking work continues at FNI with research undertaken in a number of basic and clinical areas that are aimed at developing better treatments for a range of neurological and psychiatric conditions. Examples of FNI's areas of research are below.

- Stroke
- Epilepsy
- Multiple sclerosis
- Huntington's disease
- Motor neurone disease
- Traumatic brain and spinal cord injury
- Depression
- Parkinson's disease
- Schizophrenia
- Addiction
- Brain function in health and disease
- Neuroimaging
- Discovery research

FNI not only specialises in brain and mind disease that affect millions in our community, but has the capacity to assist fellow researchers, pharmaceutical and bio-medical companies to develop and perform trials on its behalf.

WORKING TOGETHER TO IMPROVE OUTCOMES

FNI represents a powerful step forward for three reasons - programs, productivity and people.

- Neuroscience is a broad field and there are enormous benefits to be derived from sharing technologies, expertise and insights. Technology is evolving rapidly and it is important for researchers to keep pace with and share knowledge about the latest developments.
- Strength will be derived from sharing equipment and support services. Streamlined operational costs will ensure that researchers have the maximum access to state-of-the art equipment and cutting-edge expertise.
- People constitute FNI's third strength. The relocation will draw staff together with the hope that the collaborative and exciting environment will also attract leading researchers from around the world.



www.fni.edu.au

CENTRE FOR EYE RESEARCH AUSTRALIA

The Centre for Eye Research Australia (CERA) is Australia's leading eye research institute. Its mission is to eliminate the major eye diseases that cause vision loss and blindness and reduce their impact in our community.

CERA's eight research units conduct basic research to understand disease processes, clinical research to improve diagnosis and treatment of major eye diseases, population and health economics research and research into service delivery, education and program evaluation.

Through its affiliation with the University of Melbourne and links to the Royal Victorian College of Ophthalmologists (RANZCO), CERA is helping to train the next generation of eye specialists.

CERA is located at the Royal Victorian Eye and Ear Hospital. The setting provides the ideal environment to conduct its world renowned translational research.

In 2009, CERA was awarded a Centre for Clinical Research Excellence (CCRE) grant for its translational clinical research in major eye diseases by the National Health and Medical Research Council.



www.cera.org.au

MENTAL HEALTH RESEARCH INSTITUTE

The Mental Health Research Institute (MHRI) engages in research which improves the lives of people affected by psychiatric illness and dementia. The Institute, led by Director, Professor Colin Masters, focuses its work in two major research programs; Neurodegeneration and Neuropsychiatry. Links to clinical services ensure research remains relevant and allows translation of research findings into clinical practice.

NEURODEGENERATION

- Alzheimer's disease - mechanism of neurotoxicity of A-beta amyloid protein, Amyloid Precursor Protein (APP), APP processing and reagent development.
- Involvement in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, the largest longitudinal cohort study of its kind in the world, aiming to discern preclinical biomarkers, environmental contributions and treatment strategies for Alzheimer's disease.
- Endogenous and exogenous factors that predispose to dementia, especially of the Alzheimer type.
- Drug development and clinical trials, screening for dementia and pre-clinical diagnosis.
- Role of oxidative stress in neurodegenerative diseases: Alzheimer's disease, Huntington's disease, motor neurone disease, Creutzfeldt-Jakob disease and the fronto-temporal dementias and tauopathies.
- The normal and abnormal function of proteins which aggregate in these diseases and form pathogenic amyloid plaques.

NEUROPSYCHIATRY

(Schizophrenia, Bipolar Disorder, Depression and related disorders)

- Identification of key genes and proteins through genomics/proteomics.
- Regulation of major molecular therapeutic targets and neurobiological actions of dopamine, serotonin, acetylcholine and GABA.
- Behavioural/phenotypic analysis of effect of pharmacological tools and modulating action of sex steroid hormones and stress.
- Mechanism of action of atypical antipsychotics.
- Cognitive deficits in schizophrenia and mood disorders.
- Generation of delusions and auditory hallucinations (hearing voices).
- Role of oxidative free radicals in schizophrenia - fundamental and clinical studies.
- Impact and mechanism of psychosocial treatment and collaborative therapy for people with a psychiatric illness.

NEUROSCIENCE PLATFORMS

MHRI is closely involved in the following neuroscience platforms.

- Australian Brain Bank Network - lead organisation
- Neuroproteomics and Neurogenomics - Professor Colin Masters, Professor Brian Dean
- Neuro Research Services - Associate Professor Maarten van den Buuse

PLANNING FOR THE FUTURE

The planned co-location of some of MHRI's research groups in the new Parkville neuroscience facility and at the Austin Hospital in 2011, with our partners Florey Neuroscience Institutes and the University of Melbourne, will give our researchers access to greater know-how, technologies and equipment. Researchers from each of the participating organisations will form multidisciplinary teams to apply insights to related fields and to translate discoveries into new treatments.

 www.mhri.edu.au

MONASH UNIVERSITY

The Monash University Neuroscience and Mental Health Research Network and the Faculty of Medicine, Nursing and Health Sciences bring together teams of scientists and clinicians from across the University and its affiliated centres and institutes to tackle major research challenges in the field of mental health and neuroscience.

Incorporating the University campuses and many clinical sites and large teaching hospitals, Monash neuroscientists conduct leading edge research and clinical investigation in key areas of neuroscience and mental health, including: neuroimaging, neuroinflammation, developmental neuroscience, developmental brain injury, regenerative medicine, ageing and neurodegeneration, brain plasticity and repair, Huntington's disease, cognition, control of movement and emotions, anxiety disorders, Alzheimer's disease, stroke, sensory physiology, schizophrenia, depression, autism, traumatic brain injury, bipolar affective disorder and intellectual disability.

The Neuroscience and Mental Health Network facilitates multi-disciplinary, cross-faculty research collaborations, building research capacity in the neurosciences and mental health and promoting the value of neuroscience research to the community, government and industry. Combining both laboratory based science and clinical research across many fields, we translate our findings into evidence based practice, policy and training.

MONASH AT A GLANCE

- Monash is Australia's most internationalised university.
- It has more than 53,000 students from over 100 countries.
- Monash University is a member of the prestigious Group of Eight (Go8) universities, recognised for excellence in teaching, learning, research and graduate outcomes.
- Monash/Clayton cluster is home to CSIRO, the Australian Synchrotron, the Monash Medical Centre, the Australian Stem Cell Centre and the Australian Regenerative Medicine Institute (ARMi).

The research in the University is underpinned by core technology platforms.

- Structural biology
- Genomics, bioinformatics, proteomics
- High throughput protein production
- Optical imaging
- Monoclonal antibody production
- Mouse phenomics/transgenics
- Bio-imaging, drug design and development
- Biostatistics, data-management, bio-banking

The University has a strong international reputation in research, including:

- Regenerative medicine, stem cells and developmental biology
- Cardiovascular and thrombosis
- Cancer
- Structural biology and drug development
- Public health and epidemiology
- Infection and immunity
- Inflammation, allergy and autoimmunity
- Health science and global health
- Rural health
- Indigenous health
- Mental health and cognitive neurosciences

Monash University has eight campuses: six in Australia, one in Malaysia and one in South Africa as well as centres in London, UK and Prato, Italy.

MEDICINE, NURSING AND HEALTH SCIENCES

The Faculty of Medicine, Nursing and Health Sciences offers outstanding training through courses that include Medicine, Psychiatry, Behavioural Neuroscience, Biomedical Science, Psychology, Radiography and Medical Imaging. The Faculty has strong links with research institutes such as the Baker/IDI Research Institute, the Prince Henry's Institute for Medical Research, and the Macfarlane Burnet Institute for Medical Research and Public Health, as well as with our major teaching hospitals, principally Monash Medical Centre, The Alfred and Box Hill Hospitals. In total, the Faculty operates in 125 practices and 68 hospitals, providing outstanding facilities and resources for clinical teaching.



www.med.monash.edu.au

SWINBURNE UNIVERSITY OF TECHNOLOGY

Swinburne has a reputation for producing exceptional quality research that belies its relatively small size. This enviable reputation as a centre for intensive research excellence is the result of a highly focused approach. This focus has seen strong research ties with industry and participation in five National Centres of Research Excellence, including one National Health and Medical Research Council and four Australian Research Council Centres of Excellence, as well as membership of five Co-operative Research Centres. To continue this outstanding performance, Swinburne will invest \$250 million over the next four years in highly focussed areas of excellence and global competitiveness. This is all part of Swinburne's strategy for continued world-class achievements in research.

BRAIN SCIENCES INSTITUTE

The principal aim of the Brain Sciences Institute (BSI) is to conduct high quality research in human neuroscience. This includes the areas of cognitive neuroscience, neuropsychopharmacology, and translational research with a particular emphasis on applied clinical areas across the lifespan. Emphasised is not only the identification of brain structures, functions, and dynamics associated with specific conditions, but also normal development and well-being.

The BSI has brought together a multidisciplinary team of researchers that includes physicists, psychologists, psychophysicists, biophysicists and neuroscientists.

Research is undertaken using multiple neuroscientific technologies: imaging (including MRI/fMRI, MEG, EEG); stimulation (using TMS); psychophysical techniques; and cognitive, clinical and experimental measures and methodologies. In addition, clinical trials are conducted, focusing on the evaluation of effects on cognition, mental health, well-being, and specific functions (e.g. driving).

Specific areas of interest include:

- Brain dynamics and biophysics
- Cellular neuroscience
- Social and affective neurosciences
- Visual and cognitive neurosciences
- Emotional intelligence
- Herbal and nutritional medicine
- Clinical disorders and their treatment
- Normal and abnormal ageing and infant development
- The neuroscientific study of decision-making

The BSI strives to foster local and international research collaboration with government, industry and other academic institutions and has been successful in attracting nationally competitive grants, national and international industry contracts and government tenders. Further development of Swinburne's state-of-the-art neuroscience facilities will take place within the Advanced Technologies Centre (ATC) which when complete, will advance the BSI's research capacity.

Professor Michael Kyrios, Director of the BSI, is a clinical psychologist who has a long history of commitment to teaching, research and clinical practice. In addition to working in the university sector, Mike has worked in general hospital, psychiatric, rehabilitation, primary care and private practice settings. He has a particular interest in the development and dissemination of clinical applications, based on evidence emerging from basic research using a range of methodologies. This focus on translational research and the integration of methodologies and findings across the lifespan is widespread across the BSI.

BSI research staff (in alphabetical order): Associate Professor Vitas Anderson, Dr Joseph Ciorciari, Professor David Crewther (Deputy Director), Associate Professor Greg Murray, Dr Karen Hansen, Dr Patrick Johnston, Dr Jordy Kaufman, Associate Professor David Liley, Dr Andrew Pipingas, Professor Andrew Scholey, Mr David Simpson, Professor Andrew Wood.



www.swinburne.edu.au/lss/bsi/

UNIVERSITY OF MELBOURNE

The University of Melbourne continues to have an outstanding international profile in many facets of the neurosciences. Our cohort of eminent neuroscientists span the breadth of the University within the Faculty of Medicine, Dentistry and Health Science, Melbourne School of Engineering and the Faculty of Science, in particular. Research groups within these areas utilise multidisciplinary approaches to investigate a wide array of areas ranging from the neurobiology of cognitive function through to applied research designed to minimise the impact of major health care issues relevant to the spectrum of neurologic and psychiatric illness.

In recognition of the University's strength in the neurosciences, the University is actively exploring ways to further enhance its profile and capacity in the neurosciences and to foster inter-disciplinary research to optimise meaningful outcomes. Within the Faculty of Medicine, Dentistry and Health Sciences research strengths have been grouped into eight research domains, one of which is the Neurosciences and Behavioural Sciences Domain, led by Professor Trevor Kilpatrick, Director of the Faculty's Centre for Neuroscience. The research interests of these researchers are grouped into sub-domains and include: clinical neurology/neurodegenerative disease, developmental neurobiology and stem cell science, neurogenetics, neurophysiology/autonomic and sensory systems, mental health, advanced technologies (including imaging), molecular and cellular neurobiology, auditory and visual sciences, behavioural neurosciences, social psychology, clinical psychology, epilepsy, stroke, and neurotrauma. In a complementary development, a university-based institute, the Melbourne Neuroscience Institute, has also been developed. The inaugural Director of the Melbourne Neuroscience Institute is Professor Trevor Kilpatrick.

The Melbourne Neuroscience Institute is defined by a research focus directed to the neurosciences and related fields across the breadth of the University and will serve to facilitate robust interactions with other biological sciences, in addition to the physical sciences and engineering. A key objective of the Melbourne Neuroscience Institute is to build on extant links with public teaching hospitals, independent medical research institutes and commercial partners, including the pharmaceutical and medical devices industries, in order to facilitate knowledge transfer. This is especially important given that the University has entered into partnership with the Florey Neuroscience Institutes, the Mental Health Research Institute, Austin Health and Melbourne Health to develop shared facilities on the University campus at Parkville and at the Austin Hospital campus, collectively known as the Melbourne Brain Centre. Construction of the new facilities are well underway and we look forward to sharing these state of the art facilities during 2011. This development will create the largest neuroscience and mental health research facility in Australia, significantly increasing Australia's capacity to undertake medical research. The new facilities will accommodate over 700 staff and include laboratories, research offices, state of the art technologies including magnetic resonance imaging suites and a brain bank, as well as translational research facilities on the hospital campuses.

In a significant development at the University's Parkville campus, Professor Gary Egan, Associate Director of the Centre for Neuroscience, and Professor Ted Whitten of the School of Veterinary Science, spearheaded successful university engagement in collaborative bids to obtain funding

from the Commonwealth and State Governments to provide state of the art ultra-high field MR as well as PET-CT imaging capacity to the Melbourne Brain Centre.

Other major new neuroscience initiatives at the University of Melbourne include:

- A flagship program with CSIRO in stroke research to which the University contributed and is a signatory has been finalised.
- A \$5 million program supported by the Victorian Neurotrauma Initiative to develop treatments for the cardiovascular, bowel and bladder complications of spinal cord injury has commenced.
- Professor Sam Berkovic led a successful NHMRC program grant application that delivers \$16 million to neuroscience research at the University of Melbourne and partner organisations.
- Professor Trevor Kilpatrick is a Chief Investigator on an NHMRC program grant shared between the University of Melbourne and the University of Queensland.
- The Melbourne Neuroscience Institute provides the strategic focus for the \$35 million Centre for Neural Engineering initiative of which \$17.5 million has been provided by the Federal Government via the EIF scheme for infrastructure support and capacity building. The initiative involves three nodes that will comprise facilities in Engineering, the Melbourne Brain Centre, as well as a new data centre. The initiative will link with the Victorian Life Sciences Computational Initiative. Key research leaders associated with the Centre include Professor Jonathan Manton and Associate Professor Steve Petrou who will work within the engineering and neurobiology nodes, respectively.

The University of Melbourne has also elected to prioritise its activities in stem cell research and regenerative medicine both from a research and policy development perspective. To address this aspiration, the Centre for Neuroscience is actively engaged in searching for a senior investigator to assume a leadership role in this field, recognising that the considerable commitment that the Centre for Neuroscience has already made to this field with particular emphasis on the application of neural precursor cells to neurological disease.

The Centre for Neuroscience also plays an important role in maintaining the quality of the research experience and productivity of research higher degree students who are focusing on the neurosciences on campus whether their projects are undertaken within University laboratories or within independent medical research institutes. Together with Professor Sam Berkovic and Dr Kathy Lefevre of the Faculty of Medicine, Dentistry and Health Sciences Department of Medicine (Austin Health/Northern Health), the research higher degree program has been expanded with a series of discrete teaching and learning modules, an initiative made possible through the generous support of a provost grant. Through this program we hope to enhance the breadth of the knowledge-base of our students in the neurosciences, independent of the specific focus of their masters or doctoral studies.



www.unimelb.edu.au

BOARD ADVISORY COMMITTEES

RISK AND AUDIT COMMITTEE

The Risk and Audit Committee is a Committee of the NSV Board and oversees the audit and risk functions of the Company. The Committee is comprised of the Chair of the Board and non-executive Independent Directors. The primary objective of the Committee is to assist the Board in fulfilling its responsibilities by:

- overseeing the internal control functions of the Company and its corporate entities,
- reviewing the relationship of those functions to external audit,
- reviewing the financial statements and reports,
- identifying the areas of risk affecting the Company and its corporate entities,
- monitoring the Company's development, implementation and audit of policies and practices in relation to risk,
- monitoring compliance with law,
- assisting the Company to identify and manage risks and opportunities in the commercialisation of intellectual property; and
- reviewing proposals for resource allocation and making recommendations to the Board.

The Committee also oversees the activities of its subcommittee, the Remuneration Committee, which has carriage of the remuneration framework and level for the CEO as well as the CEO's performance plan.

MEMBERSHIP

- Ms Jan West AM (Chair)
- Mr Bill Burdett
- Mr Bruce Kean AM

SCIENTIFIC ADVISORY COUNCIL

The Scientific Advisory Council is a Committee of the NSV Board, established to generate initiatives and facilitate collaboration and the sharing of knowledge, skills and resources across a widely representative neuroscience community. The Council plays a role in policy development, advises the Board on scientific strategy and particular projects with the potential for commercialisation, as well as options for infrastructure enhancements to further neuroscience research. Membership comprises all major scientific groups involved with NSV, with members usually, but not exclusively, at the level of full Professor with active scientific as well as clinical involvement to reflect the importance of translational research. The Council is well placed to provide advice on scientific strategy and encourage collaboration, resource sharing and identification of new funding opportunities.

MEMBERSHIP

NAME	INSTITUTE
Dr Nick Gough - Chair	
Professor Samuel Berkovic AM	Epilepsy Research Centre
Dr James Bourne	Monash University
Professor Iain Clarke	Monash University
Professor Mark Cook	St Vincent's Hospital
Professor Kim Cornish	Monash University
Professor David Crewther	Swinburne University of Technology
Professor Jonathon Crowston	Centre for Eye Research Australia
Professor Stephen Davis	Royal Melbourne Hospital
Professor Geoffrey Donnan	Florey Neuroscience Institutes
Professor Gary Egan	Florey Neuroscience Institutes
Professor Paul Fitzgerald	The Alfred Hospital
Professor John Furness	University of Melbourne
Professor Malcolm Horne	Florey Neuroscience Institutes
Professor Graeme Jackson	Brain Research Institute
Professor Bevyn Jarrott	Florey Neuroscience Institutes
Professor Andrew Kaye	Royal Melbourne Hospital
Professor Trevor Kilpatrick	University of Melbourne
Professor Jayashri Kulkarni	The Alfred Hospital
Professor Mike Kyrios	Swinburne University of Technology
Professor Peter McIntyre	University of Melbourne
Professor Catriona McLean	The Alfred Hospital
Professor Colin Masters	Mental Health Research Institute
Dr Andrew Milner	Neurosciences Victoria
Dr Cristina Morganti-Kossmann	The Alfred Hospital
Professor Christos Pantelis	University of Melbourne
Professor Jeffrey Rosenfeld	The Alfred Hospital
Professor Ingrid Scheffer	Austin Health
Professor Rob Shepherd	The Bionic Ear Institute
Professor Ian Smith	Monash University
Professor Elsdon Storey	The Alfred Hospital
Professor Julie Stout	Monash University
Professor Bruce Tonge	Monash University

NSV TEAM

Dr Andrew Milner

CHIEF EXECUTIVE OFFICER

Andrew is the CEO of Neurosciences Victoria and Neurosciences Australia. He is also a non-executive director of STC Ltd, a micro and nano technology consortium. Andrew obtained a BSc (Hons) at the University of Melbourne in 1976, a MSC degree at the University of Melbourne in 1980 and a PhD at the John Curtin School of Medical Research at the Australian National University in 1983. Andrew is a Fellow of the Australian Society for Microbiology and has worked in animal health and agriculture as Head of Molecular Biology at the Victorian Institute of Animal Science and subsequently as Operations Manager at Daratech Pty Ltd. In the medical arena, he has worked as Pricing Manager for Zeneca and AstraZeneca in Australia, as Director of Development and Commercialisation for Kendle (Australia) and as Managing Director of Mimotopes Pty Ltd.

Irwin Saunders

CHIEF FINANCIAL OFFICER

Irwin is an FCPA of over 30 years' standing and joined NSV in January 2008. Prior to joining NSV Irwin was Finance Manager of Australian Envelopes, Australia's largest envelope manufacturer. From 1998 to 2005 he was Financial Controller and Company Secretary of Mimotopes Pty Ltd, an Australian biotechnology company. He also has extensive experience in senior finance roles in security printing and packaging as well as scientific instrumentation.

Dr Fan Li

SENIOR PROJECT OFFICER

Fan holds a Bachelor of Medicine with a major in Public Health (Beijing Medical University), a PhD in Molecular Biology/Immunology (the University of Melbourne) and a Diploma in Business and Biotechnology (RMIT). She has extensive experience working as a senior laboratory scientist in the areas of vaccine and diagnostics development. Prior to joining NSV in May 2009, Fan Li worked as Project Manager in Select Vaccines Ltd and played key roles in planning and managing the company's Research and Development portfolio.

Jackie Thompson

ACCOUNTS

Jackie commenced her employment with NSV in July 2004. She has over 20 years experience working for a variety of companies, from a small computer software business to a large manufacturing/wholesale publicly owned company and has previously worked in accounts and administration within the hospitality industry.

Marion Thompson

COMPANY SECRETARY

Marion has an extensive background in providing executive support at the senior level. Prior to joining NSV in mid 2002, Marion spent 20 years in the Victorian public sector.

Trisha Wooding

OFFICE MANAGER

Trisha has significant experience in administration and office management in both the public and private sectors and has provided support to high level executives in a number of companies. Trisha's role at NSV encompasses a broad range of activities within NSV's operations.

FINANCIALS

NEUROSCIENCES VICTORIA LIMITED
ABN 56 094 548 973

STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2010

	2010 \$	2009 \$
Revenues	1,164,465	814,943
Employee benefits expense	-626,324	-478,487
Depreciation, amortisation and impairment losses	-7,651	-8,071
Project expenditure	-25,000	-25,000
Business development expense	-33,703	-50,351
Insurance expense	-12,665	-33,779
Professional fees	-82,082	-91,929
Travel expense	-21,090	-31,199
Occupancy expense	-7,350	-14,030
AIBL study expense	-280,000	-
Other expenses	-44,186	-38,059
Profit before tax	24,414	44,038
Income tax expense	-	-
Profit for the year	24,414	44,038
Other comprehensive income / (expense)	-	-
Total comprehensive income / (expense) for the year	24,414	44,038

STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2010

	2010 \$	2009 \$
Current assets		
Cash and cash equivalents	601,854	549,236
Trade and other receivables	58,549	124,055
Other financial assets	1,600,000	1,600,000
Other assets	141,648	106,861
Total current assets	2,402,051	2,380,152
Non-current assets		
Property, plant and equipment	19,207	24,806
Financial assets	7	7
Total non-current assets	19,214	24,813
Total assets	2,421,265	2,404,965
Current liabilities		
Trade and other payables	163,063	181,996
Other liabilities	0	8,565
Employee benefit liabilities	60,965	57,595
Total current liabilities	224,028	248,156
Non-current liabilities		
Employee benefit liabilities	16,014	0
Total non-current liabilities	16,014	0
Total liabilities	240,042	248,156
Net assets	2,181,223	2,156,809
Equity		
Reserves	1,500,000	1,500,000
Retained earnings	681,223	656,809
Total equity	2,181,223	2,156,809

 www.neurosciencesvic.com.au

Neurosciences Victoria Ltd

ACN 094 548 973

Level 2, 161 Barry Street
CARLTON SOUTH VIC 3053
Australia

 +61 3 8344 1802

 +61 3 9348 1764

 info@neurosciencesvic.com.au

 www.neurosciencesvic.com.au